DOCSLIB.ORG

Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs E/NL. 1975/43 21 June 1976 UNITED NATIONS ENGLISH ONLY LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS SWEDEN Communicated by the Government of Sweden NOTE BY THE SECRETARY-GENERAL - In accordance with the relevant Articles of the International Treaties on Narcotic Drugs, the Secretary-General has the honour to communicate the following legislative text. E/NL.1975/45 Unofficial translation Proclamation of the National Board of Health and Welfare of 7 July 1974 containing schedules of narcotic drugs. According to an authorization given in the Narcotics Ordinance of 14 December 1962^ the National Board of Health and Welfare has compiled schedules of narcotic drugs as follows: 1. "Narcotics" means (a) any of the substances in Schedules I, II and III, stereoisomers (dextromethorphan and dextrorphan excepted), esters and ethers of these substances and salts of the substances, stereoisomers, esters and ethers whether crude or pure, natural or synthetic; (b) any of the substances in Schedules IV and V and salts of these substances; (c) preparations - with the exception stated below - containing substances referred to in paragraph (a) above; (d) preparations containing one or more of the substances referred to in paragraph (b) above and other preparations containing these substances provided that the National Board of Health and Welfare has so decided. 2. "Narcotics" does not refer to: (a) preparations of morphine containing not more than 0.2$ morphine calculated as anhydrous morphine base and compounded with one or more other therapeutically active, non-narcotic ingredients; (b) preparations of cocaine containing not more than 0.1$ cocaine calculated as cocaine base and compounded with one or more other therapeutically active, non-narcotic ingredients; (c) preparations not more than 100 milligrammes per dosage unit of the substances in Schedule III compounded with one or more other therapeutically active, non-narcotic ingredients and with a concentration of not more than 2.5$ in undivided preparations; 1/ Note by the Secretariat: E/NL.I964/26. - 2 - (d) preparations of difenoxin-^ containing, per dosage unit, not more than 0.5 mg of difenoxin and a quantity of atropine sulphate equivalent to at least five per cent, of the dose of difenoxin; (e) preparations of diphenoxylate containing, per dosage unit, not more than 2.5 rag of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least one per cent of the dose of diphenoxylate. NFN signifies a name confirmed by the Nordic Pharmacopoeia Committee. INN signifies that an international non-proprietary name has been proposed or recommended by the World Health Organization. SCHEDULE I "Cannabis" which means all parts above ground of the cannabis plant (except seeds), from which the resin has not been extracted, by whatever name they may be designated. "Cannabis resin" which means the separated resin, whether crude or purified, obtained from the cannabis plant. Extracts and tinctures of cannabis. 2- Amino-l-(2,5-dimetoxi-4-metylfenyl)propan (STP, DOM) N,N-Dietyl-(2-indolyl-(3)-etyl)amin (DET) 3- (2-Dimetylaminoetyl)indolol-(4) (psilocine) 3-(1,2-D imetylheptyl)-6,6,9-trimetyl-7,8,9,10-t etra- hydro-6H-dibenso[b,d]pyranol-(l) (DMHP) N,N-Dimetyl-(2-indolyl-(3)-etyl)amin (DMT) Heroin (diacetylmorfin) 3-Hexyl-6,6,9-trimetyl-7,8,9,10-t etrahydro-6H-dibenso- [b,d]pyranol-(l) (parahexyl) Hydroxi-3-pentyl-6,6,9-trimetyl-6a,7,10,10a-t etrahydro- -6H-dibenso[b,d]pyranol-(l) (hydroxitetrahydrocannabinoler) Lysergidum NFN (LSD) Meskalin 3-Pentyl-6,6,9-trimetyl-6a,7,10,10a-tetrahydro-6H- dibenso[b,d]pyranol-(l) (tetrahydrocannabinos) Psilocybinum MEN [Psilocybine] _3_/ SCHEDULE II Acetorphinum NPN Acetorphinel 3/ Acetyldihydrokodein Acetyldihydro codeine] Acetylmethadolum NFN Acetylmethadol1 Allylprodinum NFN Allylprodine] Alphacetylmethadolum NFN Alphacetylmethadoll Alphameprodinum NFN Alphameprodine| Alphamethadolum NFN Alphamethadol] Alphaprodinum NPN Alphaprodine Amfepramonum NPN Amphepramone Amphetaminum NFN Amphetamine] 2/ Note by the Secretariat; International non-proprietary names of drugs are underlined. _3_/ Note by the Secretariat: The words in square brackets have been inserted by the Secretariat; international non-proprietary names of drugs are underlined. - 3 - Anileridinum NFN Anileridine] Benzethidinum NFN Benzethidinel Bensylmorfin (3-bensylmorfin) Benzylmorphine] Betacetylmethadolum NFN Betacetylmethadoll Betameprodinum NFN Betameprodine1 Betamethadolum NFN Betamethadoll Betaprodinum NFN Betaprodine_ Bezitramidum NFN Bezitramide Clonitazinum HEN Clonitazene Cocainum NFN CocaineJ Codoximum NFN Codoxime] Desomorphinum BEN Desomorphine] Dexamphetaminum NFN Dexamphetamine _ Dextromoramidum NFN Dextromoramide1 Diaethylthiambutenum NPN Biethylthiambutene] Diampromidum NFN Diampromide] Difenoxinum NFN Difenoxin | D ihydrocode inum NFN D ihydro co de ine] D ihydromo rf in (3,6-dihydroxi-17- -metyl-4,5-epoxi- morfinan) Dihydromorphine] Dimenoxadolum NFN Dimenoxadol] Dimepheptanol NFN Dimepheptanol1 Dimethylthiambutenum NFN Djjmethylthiambutenel (-)-1-Dimetylamino-l,2- -difenyletan (SPA) Dioxaphetyli butyras INN Dioxaphetyl butyrate] Diphenoxylatum NFN Diphenoxylate | Dipipanonum NFN Dipipanone Drotebanolum NFN Drotebanol Ekgonin samt estrar och Ecgonine] derivat darav, som kan 6'verforas i ekgonin eller kokain Ethylmethylthiambutene Ethylmethylthiambutene] Etonitazinum NFN Etonitazene | Etorphinum NFN Etorphine] Etoxeridinum NFN Etoxeridine] Etylamfetamin (2-etyl- amino-l-fenylpropan) Ethylamphetamine] Fentanylum NFN Fentanyll (1-Fenyl-l-piperidyl-(2) -metyljacetat Furethidinum NFN [Furethidine Hydroconum NFN THydrocodone (Hydrocodonum Iffl) Hydromo rphinolum NFN Hydromorphino11 Hydromorphonum NFN Hydromorphonel Hydroxiamfetamin Hydroxyamphetamine] Hydroxypethidinum INN Hydroxypethidine] Isomethadonum NFN Isomethadone Ketobemidonum NFN Ketobemidone Kokablad Coca leaf] Koncentrat av vallmohalm Concentrate of poppy straw] Levometorphanum NFN Levomethorphan] Levomoramidum NFN Levomoramide | - 4 Levophenacylmorphanum NFN Levophenacylmorphan] Levorphanolum NFN Levorphanol] Metadonint ermediat Methadone Intermediate] (2,2-difenyl-4-dimetyl- aminopentannitril) Metazocinum NFN Metazocine] Methadomun NFN Methadone 1 Methamphetaminum KPN Methamphetamine] Methyldesorphinum NFN Methyldesorphine] Methyldihydromorphinum NFN Methyldihydromorphine] Methylphenidatum NFN Methylphenidat e j Metoponum NFN Metpon] Moramidint ermediat Moramide Intermediate] (2,2-difenyl-3-metyl-4- -mo rfo1ino smorsyra) Morf inmetylbromid [Morphine Methobromide] och andra morfinderivat med femvardigt kvave Morfin-N-oxid [Morphine-N-Oxide] Morpheridinum KPN [Morpheridine] Morphinum KPN [Morphine] Myrophinum KPN Nicomorphinum KPN Noracymethadolum NPN Norlevorphanolum KPN Normethadonum NPN Normorphinum KFN Norpipanonum HFN Opium NFN [Opium] Oxiconum NFN [Oxycodone] (Oxycodonum INN) Ox imo rpho num KPN Oxymorphone] Pethidinum KFK Pethidine] Petidinintermediat A Pethidine, Intermediate A] (4-fenyl-l-metylpiperi- dinkarbonitril-(4)) Petidinintermediat B [Pethidine, Intermediate B] (etyl-(4-fenylpiperidinkar- boxylat-(4))) Petidinintermediat C [Pethidine, Intermediate C] (4-fenyl-l-metyl- piperidinkarboxylsyra-(4)) Phenadoxonum KPN Phenadoxone] Phenampromidum KPN Phenampromide] Phenazocinum KFN Phenazocine] Phencyclidinum KFN Pheneyclidine] Phendimetrazinum NPN Phendimetrazine] Phenmetralinum NPN Phenmetrazine] (Phenmetrazinum INN) Phenomorphanum KPN Phenomorphan] Phenoperidnum KFN Phenoperidine] Phent erminum KFN Phentermine J Piminodinum KFN Piminodine] Pipradrolum KFK PipradrolJ Piritramidum KFN Piritramide] Proheptazinum NFN Proheptazine] Properidinum NFN Properidine] - 5 - Racemethorphanum NFN rRacemethorphan] Ra c emo ram i dum NFN Racemoramide | Racemorphanum NFN rRacemorphan] Thebaconum NFN ThebaconT Thebainum Thebaine (3,6-dimetoxi-17-metyl- -4,5-epoximorfinadien- -(6.8)) Trimeperidinum NFN [Trimeperidine 1 SCHEDULE III Aethylmorphinum HEN [Ethylmorphine] Codeinum NEK ~ Codeine] Nicocodinum NFN Nicocodine] Nicodicodinum NEN Nicodicodine] Norcodeinum NEN Norcodeine Pholcodinum NEN 'Pholcodine" Propiramum NEN Propiram] Nitrazepamum NPN Nitrazepam] Oxazepamum NFN Oxazepam Pentymalum NEN [Pentymal" SCHEDULE IV Allypropymalum NFN Allylpropymal] Butenemalum NFN Butenemal] Chlordiazepoxidum NFN Chlordiazepoxide] Clomethiazolum NFN Clomethiazole| Diallymalum NFN Diallymal] Diazepamum NFN Diazepam] Dikalii chlorazepas NEN Glutethimidum NFN Glutethimide] Heptamalum NFN Hexapropymatum NFN Hexapropymate] Hexemalum NFN Meballymalum NFN Mebumalum NFN _Mebumal] Meprobamatum NFN Meprobamate] SCHEDULE V Chlorali hydras NFN Chloralodolum NFN Chloralodol] Diemalum NFN Diemal] Ena11ynymalum NFN Methohexital] Enhexymalum NFN EnhexymalJ Enphenemalum NFN Enphenemal_ Ethinamatum NFN "Ethinamate Etklorvynol (e-etyl-1- Ethchlorvynol] -klorpenten-(l)-in-(4)-ol-(3) Methaqualonum NFN Methaqualone] Methylpentynolum NFN Methylpentynol] Methyprylonum NFN Methyprylon] Phenemalum NFN Tybamatum NFN [Tybamate] This decree enters into force on 1 October 1974, on which date the list of narcotics of the National Board of Health and Welfare of 7 June 1972 (MF No.3l),4/ shall oease to be valid. Hedengren, Wahlqvist, Bdttiger, Krook (General Drug Division) 4/ Note by the Secretariat: E/NL.1973/28. .
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Förordning Om Ändring I Förordningen (1992:1554) Om Kontroll Av Narkotika;
    Príloha 11 k rozhodnutiu švédskych úradov vlády 22. februára 2018 § 79 1. ------IND- 2018 0079 S-- SK- ------ 20180302 --- --- PROJET Zbierka zákonov Švédska SFS Published on issued on 1 March 2018. The government hereby lays down1 that Annex 1 to the Ordinance (1992:1554) on the control of narcotic drugs2 shall read as set out below. This ordinance shall enter into force on 10 April 2018. On behalf of the Government ANNIKA STRANDHÄLL Lars Hedengran (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Ordinance reprinted as 1993:784. 1 SFS Annex 13 List of substances to be considered narcotic drugs according to the Narcotic Drugs Punishments Act Stimulants of the central nervous system ethylamphetamine (2-ethylamino-1-phenylpropane) fenethylline [1-phenyl-1-piperidyl-(2)-methyl]acetate 1-phenyl-2-butylamine N-hydroxyamphetamine propylhexedrine 4-methylthioamphetamine (4-MTA) modafinil 4-methoxy-N-methylamphetamine (PMMA, 4-MMA) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) 4-iodo-2,5-dimethoxyphenethylamine (2C-I) 2,4,5-trimethoxyamphetamine (TMA-2) 4-methylmethcathinone (mephedrone) 4-fluoramphetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one (methedrone) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one (MDPV) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Hexapropymate Self-Poisoning Where Are the Untreated Depressives?
    BRITISH MEDICAL JOURNAL 17 JUNE 1978 1593 lying disease. In those described by Lowenstein and Gallo' renal 62 1 mg/100 ml), arterial pH 7 053, Pco2 6-25 kPa (47 mm Hg), Po2 15-3 kPa deposits of amyloid persisted despite clinical remission of the (115 mm Hg), bicarbonate 13-8 mmol(mEq)/l. The blood and urine con- Br Med J: first published as 10.1136/bmj.1.6127.1593-a on 17 June 1978. Downloaded from nephropathy. Both our patients had spontaneous remissions of tained no salicylates, barbiturates, glutethimide, or paracetamol. Urine nephrotic syndrome without treatment for the underlying disease. In analysis, verified against known samples of hexapropymate, showed ex- cretions of 878 mg, 197 mg, and 80 mg of hexapropymate on the first three one the urine became protein free and in the other the proteinuria days respectively after admission. Electrocardiograms showed sinus rhythm, became trivial. In both the serum albumin concentration returned to apparent short P-R intervals, delta waves, and rSR pattern in chest leads normal. Yet renal biopsy specimens before and after the period of Vl and V2, suggestive of a type B Wolff-Parkinson-White syndrome (see remission in case 1 showed progression of amyloid deposition. In figure). Liver function tests showed mild hepatocellular damage which both patients amyloidosis eventually led to chronic renal failure. gradually resolved. Interest grows in new treatments for amyloidosis.4 Whatever the His rectal temperature rose to 37°C over 12 hours, but he remained deeply mechanisms underlying the spontaneous fluctuations in the nephro- unconscious with absent reflexes for four days.
    [Show full text]
  • Video Course Evaluation Form My Name Is
    Garden State CLE 2000 Hamilton Avenue Hamilton, New Jersey 08619 (609) 584-1924 – Phone (609) 584-1920 - Fax Video Course Evaluation Form My Name is: __________________________________________ Name of Course: ______________________________________ My Street address: _____________________________________ City: _____________________ State: _____ Zip Code: ____ Email Address: ________________________________________ Please Circle the Appropriate Answer Instructors: Poor Satisfactory Good Excellent Materials: Poor Satisfactory Good Excellent CLE Rating: Poor Satisfactory Good Excellent Required: Secret words that appeared on the screen during the seminar. 1) __________________________ 2) _______________________ 3) __________________________ 4) _______________________ What did you like most about the seminar? _____________________________________________________________ _____________________________________________________________ What criticisms, if any, do you have? _____________________________________________________________ _____________________________________________________________ I certify that I watched, in its entirety, the above-listed CLE Course. Signature ___________________________________ Date_________ In order to receive your CLE credits, please send our payment and this completed form to Garden State CLE, 2000 Hamilton Avenue, Hamilton, New Jersey, 08619. BURLINGTON COUNTY BAR ASSOCIATION --- Interpreting Your Client’s Drug Lab Results: Were They Impaired? © Chris Baxter 2020 DO LAB RESULTS MATTER IN A DUI-D? YES ➢State
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Was Marketed and Are Still Occumng. 168' 1699 172, 173, 175, 177-182, 185 Meprobamate Has Been Shown to Pro- 176
    40 H. ISBELL & T. L. CHRUSCIEL CARBAMIC ACID ESTERS OF GLYCOLS Of the drugs listed in Table VI, carisoprodol 168. Bulla, J. D., Ewing, J. A. & Buffaloe, W. J. (1959) (S 103), emylcamate (S 104), mebutamate (S 107) Amer. Practit., 10, 1961 (Further controlled and phenprobamate (S 110) are not used primarily studies of meprobamate) as central nervous system depressants but are 169. Czerwenka-Wenkstetten, H., Hofmann, G. & recommended either for hypertension (S 107) or as Kryspin-Exner, K. (1965) Wien. med. Wschr., 115, 1012-1016 (Tranquillizersucht und Miss- " muscle relaxants " (S 103, S 104 and S 110). Some brauch) newly introduced drugs, buramate (S 102) and 170. Domino, E. F. (1965) In: DiPalma, J. R., ed., pentabamate (S 109), have been marketed as " tran- Drill's pharmacology in medicine, 3rd ed., quillizers" and hexapropymate (S 105) and oxy- pp. 356-364, McGraw-Hill, New York (Chap- fenamate (S 106) are used as sedatives. All these are ter 24: Psychosedative drugs. II. Meprobamnate, weak drugs and have not been abused or shown to chlordiazepoxide and miscellaneous agents) have abuse potential in animal or human experi- 171. Essig, C. F. (1958) Arch. Neurol. Psychiat. (Chic.), ments. 80, 414-417 (Withdrawal convulsions in dog Tybamate (S 111) used as a sedative has had an following chronic meprobamate intoxication) especially good animal and experimental work-up 172. Essig, C. F. & Ainslie, J. D. (1957) J. Amer. med. for abuse potential. 167, 170, 174, 187 It appears to be a Ass., 164, 1382 (Addiction to meprobamate) very weak, short-acting drug of no or very low 173.
    [Show full text]
  • List of Ingredients Prohibited in Cosmetic Products This Rule Has Been Translated Into English According to the Original Chinese Version
    List of Ingredients Prohibited in Cosmetic Products This rule has been translated into English according to the original Chinese version. If there is any inconsistency or ambiguity between these two versions, the Chinese version shall prevail. No. Chemical name CAS No. Mercury and its compounds (with the exception of the substance listed in the “List of Preservatives in Cosmetic Products”) 1 7439-97-6 Due to the raw material or other technically unavoidable reasons, the trace amounts of Mercury shall not exceed 1 ppm. 103-16-2/ 2 4-Benzyloxyphenol and 4-ethoxyphenol 622-62-8 3 Bithionol 97-18-7 4 Pilocarpine and its salts 92-13-7 5 Halogeno-salicylanilide - 10043-35-3/ 6 Boric acid 11113-50-1 7 Sodium perborate 7632-04-4 Sodium borate 8 1330-43-4 except for sodium borate used to emulsify beeswax or bleached beeswax, which content should not exceed 0.76% 9 Chlorofluorocarbons - 10 3'-Ethyl-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'- acetonaphthone or 7-acetyl-6-ethyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphtalen (AETT; Versalide) 88-29-9 11 Cells, tissues or products of human origin - Hydroxy-8-quinoline and its sulphate 148-24-3/ 12 For use as stabilizer of hydrogen peroxide in hair dyes and perming products, the content should not exceed 0.03% (calc. as base) 134-31-6 13 Dichloromethane 75-09-2 14 4-tert-Butyl-3-methoxy-2,6-dinitrotoluene (Musk ambrette) 83-66-9 15 6-Methylcoumarin (Non-medical toothpaste and mouthwash are otherwise specified by law) 92-48-8 16 Vinyl chloride monomer 75-01-4 17 2,2'-Dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane (Hexachlorophene (INN)) 70-30-4 18 Tretinoin (INN) (retinoic acid and its salts) 302-79-4 19 4-Amino-2-nitrophenol 119-34-6 20 Antimony and its compounds 7440-36-0 Arsenic and its compounds 21 7440-38-2 Due to the raw material or other technically unavoidable reasons, the trace amounts of Arsenic shall not exceed 3 ppm.
    [Show full text]
  • POISONS LIST APPENDIX Amoebicides: Carbarsone
    POISONS LIST APPENDIX Amoebicides: Carbarsone Clioquinol and other halogenated hydroxyquinoline compounds Dehydroemetine; its salts Diloxanide; its compounds Dimetridazole Emetine Ipronidazole Metronidazole Pentamidine; its salts Ronidazole Anaesthetics: Alphadolone acetate Alphaxolone Desflurane Disoprofol Enflurane Ethyl ether Etomidate; its salts Halothane Isoflurane Ketamine; its salts Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine Diperodon Etidocaine Levobupivacaine Lignocaine Mepivacaine Orthocaine Oxethazaine Phenacaine Phenodianisyl Prilocaine Ropivacaine Phencyclidine; its salts Propanidid Sevoflurane Tiletamine; its salts Tribromoethanol Analeptics and Central Stimulants: Amiphenazole; its salts Amphetamine (DD) Bemegride Cathine Cathinone (DD) Dimethoxybromoamphetamine (DOB) (DD) 2, 5-Dimethoxyamphetamine (DMA) (DD) 2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD) Ethamivan N-Ethylamphetamine; its salts N-Ethyl MDA (DD) N-Hydroxy MDA (DD) Etryptamine (DD) Fencamfamine Fenetylline Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane Leptazol Lobelia, alkaloids of Meclofenoxate; its salts Methamphetamine (DD) Methcathinone (DD) 5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD) Methylenedioxyamphetamine (MDA) (DD) 3, 4-Methylenedioxymetamphetamine (MDMA) (DD) Methylphenidate;
    [Show full text]